Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bellevue.ch, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Target group of the sites 

The sites are intended exclusively for use by legal entities and natural persons having their registered office or residing in countries in which the investment funds or the related subfunds or share classes of the Bellevue Group have been properly licensed or approved for public offer or sale in accordance with the applicable local legislation. The funds are currently registered for public distribution offer in the following countries: Luxembourg, Switzerland, Germany, Austria, Spain and Portugal. In all other countries, the funds may, if any, via "Private Placement" according to the local applicable laws.

It is explicitly stated, that alternative fund products are not allowed for public distribution in any country and that they may only and exclusively be solicited to institutional and qualified private investors according to the applicable local laws of each country.

The information and services provided on the sites are not intended for offer to or use by legal entities or natural persons in legal jurisdictions or countries in which the offer or use thereof would violate local legislation or legal provisions, or in which business units forming part of Bellevue Group would be subject to registration requirements in such jurisdictions or countries. Legal entities or natural persons to which such prohibitions apply must not access or use these sites.

The Bellevue funds have NOT been licensed for public offer or sale to the public in the United States in accordance with the US Investment Company Act of 1940 or the US Securities Act of 1933, or in Canada, Japan, Taiwan, Malaysia, Hong Kong or Israel in accordance with the laws in force in those countries. Therefore, particular importance is attached to ensuring that these sites are not intended for legal entities or natural persons, who have their registered office or who reside in such countries, their territories or dependencies or who, on account of their citizenship or similar status, are subject to the law of one of these countries.

Fund documents Luxembourg Fund

Bellevue SICAV: The Bellevue Funds (Lux) SICAV is admitted for public offering and distribution in Switzerland . Representative agent in Switzerland   Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne and paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG Münsterhof 12, PO Box, CH-8022 Zürich. Austria: Paying and information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Germany: information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Spain: The Bellevue Funds (Lux) SICAV is registered with the CNMV under the number 938. Paying and information agent: atl Capital, Calle de Montalbán 9, ES-28014 Madrid.  Prospectus, Key Investor Information Document (“KID”), the articles of association as well as the annual and semi - annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht. 

Bellevue Asset Management (Deutschland) GmbH: You can obtain the sales prospectus, the annual reports and the german key investor information documents free of charge from Bellevue Asset Management (Deutschland) GmbH, and also from banks and financial advisers. Paying agent in Switzerland is DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, PO Box, CH-8022 Zurich. The swiss agent is IPConcept (Schweiz) AG, In Gassen 6, PO Box, CH-8022 Zurich. In Switzerland you can obtain sales prospectus, the annual reports and the german key investor information documents free of charge from the agent and also from the paying agent. 

Fund documents Bellevue Entrepreneur Switzerland

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Fund under Swiss law are available free of charge from: Switzerland : PMG Fonds Management AG, Dammstrasse 23, 6300 Zug or Bellevue Asset Management AG, Seestrasse 16, CH - 8700 Kusnacht. 

Fund documents Bellevue Funds and Bellevue Healthcare Strategy

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Medtech and Services fund established under Swiss law in the category "Other Funds for Traditional Investments" are available free of charge from : Switzerland : Swisscanto Fondsleitung AG, Bahnhofstrasse 9 , CH - 8001 Zürich or Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht

Fund documents StarCapital Equity Value plus, StarCapital Multi Income, StarCapital Strategy 1 and StarCapital Dynamic Bonds.

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual report are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the relevant custodian bank or from the management company IPConcept (Luxembourg) S.A. (société anonyme), 4, rue Thomas Edison, L-1445 Luxembourg, Luxembourg, https://www.ipconcept.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.ipconcept.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Fund documents Bellevue Option Premium fund

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Universal-Investment-Gesellschaft mbH, Theodor-Heuss-Allee 70, D-60486 Frankfurt am Main, https://www.universal-investment.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

 Fund documents StarCapital Premium Bonds plus  

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports. These can be obtained free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Donner & Reuschel AG, Ballindamm 27, 20095 Hamburg, https://www.donner-reuschel.de. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. 

The current wave of innovation in the medical technology sector has created new blockbuster markets and given sector sales and profit growth a sustained acceleration. The most attractive areas include surgical robotics, diabetes treatment and minimally invasive procedures for structural heart disease.

New blockbuster markets in the medtech sector

The current wave of innovation in the medical technology sector has created new blockbuster markets and given sector sales and profit growth a sustained acceleration. The most attractive areas include surgical robotics, diabetes treatment and minimally invasive procedures for structural heart disease.
05.07.2024 - Stefan Blum, Marcel Fritsch

The latest surgical robot system also a platform for AI applications

The latest generation of the da Vinci 5 (dV5) surgical robot from Intuitive Surgical has 10,000 times more computing power than its predecessor, which will enable the launch of new AI-based applications. AI capability could soon make robot-assisted surgery standard practice in the operating room. New, advanced sensors allow the dV5 to simulate haptic feedback, which helps surgeons to perform with greater confidence and accuracy. During an operation, data is collected through sensors and images that can then be used for objective performance feedback or to create individual training plans. In the long term, this data could conceivably enable complex AI applications that, for example, recognize different types of tissue or offer surgeons recommendations during surgery. Hardware upgrades include AR glasses for image transmission and the integration of an insufflator. These enhancements improve surgical precision and reduce operation time.

Intuitive Surgical will continue to market its predecessor system da Vinci Xi, enabling them to establish different price segments for surgical robots in the process. The dV5 was launched in the US in the first quarter of 2024 and will be launched in other countries during the course of 2025. Intuitive Surgical offers its customers flexible leasing agreements that allow them to upgrade from an older to a newer generation product, so the roll-out of dV5 should not result in a temporary dip in growth for Intuitive Surgical. Xi systems returned by customers upgrading to dV5 can be placed in more price-sensitive markets, which will expand Intuitive Surgical’s installed base and thus strengthen the main sales engine of its business, which is selling robotic instruments and accessories. The dV5 is expected to lead to an acceleration in sales growth, higher unit selling prices, and better profit margins. At the same time, Intuitive Surgical’s launch of its next-generation surgical robot extends its lead over competitors such as Medtronic and Johnson & Johnson. The market potential is huge: In the US alone, 3.8 million general surgery procedures, 3.3 million cardiothoracic procedures, and 2.5 million urology and gynecology procedures are performed every year. We estimate that the surgical robots market for soft tissue surgery will double in size from USD 7.5 bn in 2024 to approximately USD 15 bn in 2028.

Continuous glucose monitors: A USD 20 billion market thanks to new products from Abbott and Dexcom

Completely new customer target groups have emerged in the field of diabetes. Dexcom, for example, recently brought Stelo, a glucose biosensor approved by the FDA in March, to the market. This sensor is designed for people with diabetes who do not use insulin to better understand how diet and exercise may impact blood sugar levels. Abbott followed suit in June when the FDA approved its Lingo biosensor. Both sensors can be bought over the counter, i.e., without a prescription. We expect the global market volume for continuous glucose monitoring systems in 2028 to be well above USD 20 bn (2023: USD 10 bn) and that Abbott and Dexcom will have a combined market share of about 90%. Insulin pump manufacturers such as Insulet could also benefit from the rapid growth of glucose biosensors. This is because at some point in the future, most people with type 1 diabetes will be wearing a biosensor, making it easier for them to transition to a fully integrated insulin delivery system, i.e., there will be less need for information and education on how to use the new product.

New procedure for cardiac arrhythmias with high growth potential

Structural heart disease, especially faulty heart valves, is also a major growth driver in the medical technology market. Minimally invasive surgical procedures are already standard for aortic heart valve replacement. The global market volume for transcatheter aortic valve replacement is forecast to reach USD 10 bn in 2028. The recent US approval of Evoque from Edwards Lifesciences, the world’s first transcatheter tricuspid valve replacement system, has opened up an entirely new market whose long-term potential is comparable to that of aortic valves. Mitral valve surgery, which is currently dominated by repair procedures such as the MitraClip (Abbott) or the Pascal Precision system (Edwards Lifesciences), is another area where an alternative solution could soon be cleared for marketing. Breakthrough data from Edwards Lifesciences’ trial of its M3 transcatheter mitral valve replacement system is expected in early 2025.

Treatment options for cardiac arrhythmia, atrial fibrillation in particular, have been enhanced with the emergence of a new non-thermal ablation procedure known as pulsed field ablation (PFA). This innovative technology is likely to supplant conventional cryoablation (extremely cold temperatures) or radiofrequency ablation (heat) procedures because it is safer and faster. Thanks to the advantages of PFA, market volume could grow from currently zero to USD 6 bn in 2028. Boston Scientific and Medtronic are both marketing PFA products backed by excellent clinical trial data. Two other industry heavyweights, Johnson & Johnson and Abbott, are about to enter the market with new products of their own.

Tailwinds for investors

These developments illustrate the impressive range of groundbreaking innovation typical of the medtech sector, along with the attractive investment opportunities that it offers. The Bellevue Medtech & Services Fund (ISIN B-EUR LU0415391431) invests in precisely these high-growth areas through a portfolio of 40 to 60 stocks with a high 90% large-cap weighting that enhances portfolio stability.

Authors

  • PortfolioManager

    PortfolioManager

    Stefan Blum

    Stefan Blum joined Bellevue Asset Management in 2008 and is portfolio manager of the funds Bellevue Medtech & Services and Bellevue Digital Health. Prior to joining Bellevue Asset Management, he spent 4 years as head of investor relations at Sonova. As a financial analyst at Bank Sarasin, he covered medical technology and high tech stocks. After that he served as CFO of Obtree Technologies Inc.  Stefan Blum obtained a degree in business administration from the University of St. Gallen and is CEFA charterholder.

  • PortfolioManager

    PortfolioManager

    Marcel Fritsch

    Marcel Fritsch joined Bellevue Asset Management in 2008 as portfolio manager of the  Bellevue Medtech & Services and Bellevue Digital Health Fund. Prior to that, he spent more than 3 years as a consultant with Deloitte & Touche. Formulating company strategy, evaluating organizational structures and valuing companies prior to corporate transactions were among his duties in this function. Marcel Fritsch holds a degree in business economics from the University of St. Gallen (HSG).

These investment strategies might interest you